Procept Biorobotics Corp (PRCT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Procept Biorobotics Corp stock (PRCT) is currently trading at $24.94. Procept Biorobotics Corp PS ratio (Price-to-Sales) is 4.72. Analyst consensus price target for PRCT is $32.27. WallStSmart rates PRCT as Sell.
- PRCT PE ratio analysis and historical PE chart
- PRCT PS ratio (Price-to-Sales) history and trend
- PRCT intrinsic value — DCF, Graham Number, EPV models
- PRCT stock price prediction 2025 2026 2027 2028 2029 2030
- PRCT fair value vs current price
- PRCT insider transactions and insider buying
- Is PRCT undervalued or overvalued?
- Procept Biorobotics Corp financial analysis — revenue, earnings, cash flow
- PRCT Piotroski F-Score and Altman Z-Score
- PRCT analyst price target and Smart Rating
Procept Biorobotics Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Procept Biorobotics Corp (PRCT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Procept Biorobotics Corp (PRCT) Key Strengths (1)
104.94% of shares held by major funds and institutions
Procept Biorobotics Corp (PRCT) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 4.7x annual revenue
Premium pricing at 4.0x book value
Small-cap company with higher risk but more growth potential
Solid revenue growth at 11.90% per year
Procept Biorobotics Corp (PRCT) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (4.72), Price/Book (3.98) suggest expensive pricing. Growth concerns include Revenue Growth at 11.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -24.90%, Operating Margin at -40.60%, Profit Margin at -31.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -24.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 11.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRCT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRCT's Price-to-Sales ratio of 4.72x sits near its historical average of 4.69x (40th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 6% below its historical high of 5.01x set in Mar 2026, and 15% above its historical low of 4.12x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~4.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Procept Biorobotics Corp (PRCT) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Procept Biorobotics Corp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 308M with 12% growth year-over-year. The company is currently unprofitable, posting a -31.0% profit margin.
Key Findings
The company is unprofitable with a -31.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Procept Biorobotics Corp.
Bottom Line
Procept Biorobotics Corp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(25 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:22:00 AM
About Procept Biorobotics Corp(PRCT)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. The company is headquartered in Redwood City, California.